Details of the Drug Combinations

General Information of This Drug (ID: DMC5SAW)

Drug Name

LY3039478 DMC5SAW

Synonyms

LY3039478; Crenigacestat; 1421438-81-4; LY-3039478; UNII-923X28214S; 4,4,4-Trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-benzo[d]pyrido[2,3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide; 923X28214S; butanamide, n-[(1s)-2-[[(7s)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5h-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro-; Butanamide, N-((1S)-2-(((7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido(3,2-a)(3)benzazepin-7-yl)amino)-1-methyl-2-oxoethyl)-4,4,4-trifluoro-

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
T-cell acute lymphoblastic leukaemia	2A90.5	Phase 1/2	[2]
Lymphoma	2A80-2A86	Phase 1	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dexamethasone + LY3039478	DC9VLXR	Dexamethasone	T-cell Acute Lymphoblastic Leukemia	[4]
LY2835219 + LY3039478	DC3RV09	LY2835219	Solid Tumor	[1]
LY3039478 + LY2940680	DCI74MA	LY2940680	Solid Tumor	[1]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02784795) A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT01695005) A Study of LY3039478 in Participants With Advanced Cancer. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT02518113) A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL